Sign inJoin waitlistJoin the waitlist

PK

Patrick Kelly

Pediatrics / Pediatric Hematology-Oncology

Credentials: ·

Research

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Blood · 2018 · 253 citations
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Blood · 2018 · 204 citations
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
American Journal of Hematology · 2018 · 51 citations

SH
Steven Horwitz
4 papers
VZ
Virginia Zaleskas
4 papers
BK
Brad Kahl
3 papers
HS
Howard Stern
3 papers
IF
Ian Flinn
3 papers
JS
Jennifer Sweeney
3 papers
Manish Patel
3 papers
Pierluigi Porcu
3 papers
YO
Yasuhiro Oki
3 papers
Francine Foss
2 papers
Jan Burger
2 papers
JJ
Jeffrey Jones
2 papers